Alliance launches study of immunotherapy to prevent lung cancer recurrence

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

As people continue to live longer and the survival rate of cancer diagnoses increases, researchers from VCU Massey Comprehensive Cancer Center decided to lead a multi-decade analysis studying the rates of subsequent primary cancers, which are new cancers unrelated to the original diagnosis.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Alliance digital tool proves effective at keeping patients engaged in trials

A pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal. Alliance created PEP to foster direct connection between cancer researchers and the individuals who volunteer for clinical studies. The goal was to make it easier for patients and clinicians to share information, deliver trial updates, and self-report on social risk factors.

June 18, 2026

Vol.52 No.24

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.

June 05, 2026

Vol.52 No.22

In Brief

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Labcorp and the Alliance for Clinical Trials in Oncology will collaborate on a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer.

June 05, 2026

Vol.52 No.22

Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Alliance launches study of immunotherapy to prevent lung cancer recurrence

YOU MAY BE INTERESTED IN

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

Alliance digital tool proves effective at keeping patients engaged in trials

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

Renew today!

Subscriber content

Never miss an issue!

Login